A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the best dose of nebulized arformoterol, a quick
onset but long acting beta agonist, for use in treating acute bronchospasm in asthmatics
presenting to the the Emergency Department. Also this study will evaluate the side effect and
safety profile of arformoterol when used in this situation.